Tilray Medical begrüßt die positiven Entwicklungen im deutschen Rechtsrahmen für medizinisches Cannabis und setzt sich für dessen kontinuierliche Weiterentwicklung ein
CompaniesTilray MedicalTilray Brands, Inc.
Signals
Every pharma-relevant, de-duplicated event surfaced so far, primary source first. Client-scoped signals are never shown here.
Tilray Medical Welcomes Progress in Germany’s Medical Cannabis Framework and Supports Continued Policy Development
CompaniesTilray MedicalTilray Brands, Inc.
SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million
CompaniesSciSparc LtdNeuroThera Labs Inc
Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
CompaniesPropanc Biopharma, Inc.AssetsPRPDiseasesadvanced solid tumorspancreatic cancerovarian cancerprostate cancer
Direct Meds Updates DirectMax Clinical Review and Licensed-Pharmacy Fulfillment Details (2026)
CompaniesDirect MedsAssetsDirectMax
Gilead Sciences Announces Second Quarter 2026 Financial Results
CompaniesGilead SciencesAssetsBiktarvyTrodelvyLivdelziVekluryHepcludexYescartaTecartusDiseasesHIVchronic hepatitis B viruschronic hepatitis delta virustriple-negative breast cancerB-cell lymphomamultiple myelomaprimary biliary cholangitis
Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026
CompaniesFractyl Health
Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates
CompaniesFractyl Health, Inc.
European Commission (EC) adopts decision to revoke marketing authorisation for TAVNEOS® (avacopan) in the European Union and European Economic Area countries
CompaniesVifor Fresenius Medical Care Renal PharmaCSLChemoCentryxAmgenAssetsTAVNEOSavacopanDiseasesgranulomatosis with polyangiitismicroscopic polyangiitis
A further update on TAVNEOS® (avacopan) in the European Union
CompaniesCSLVFMCRPAssetsTAVNEOSavacopanDiseasesANCA-associated vasculitis
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
CompaniesCrinetics PharmaceuticalsVertex PharmaceuticalsAssetsPALSONIFY (Paltusotine)
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
CompaniesBristol Myers Squibb
BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
CompaniesBioNTechPfizerBristol Myers Squibb CompanyOncoC4Duality Biologics (Suzhou) Co. Ltd.AssetspumitamigB7-H3-targeting ADC candidate elfetabart drozuntecantrastuzumab pamirtecangotistobartDiseasesnon-small cell lung cancercolorectal cancergastric cancertriple-negative breast cancersquamous NSCLCplatinum-resistant ovarian cancerendometrial cancerrenal cell carcinomahepatocellular carcinomaglioblastomapancreatic ductal adenocarcinoma
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
CompaniesBiomea FusionDiseasesType 2 diabetesobesity
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
CompaniesBiomea FusionAssetsicovamenibsemaglutideDiseasesobesity
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
CompaniesBioAge Labs
Submission of New Drug Application for Fezolinetant in Japan for the Treatment of Vasomotor Symptoms Associated with Menopause
CompaniesAstellasAssetsfezolinetantDiseasesvasomotor symptoms associated with menopause
Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
CompaniesAscendisAssetsTransCon CNPTransCon hGHYUVIWELDiseasesachondroplasia
Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026
CompaniesAscendis Pharma
Ascendis Pharma Reports Second Quarter 2026 Financial Results
CompaniesAscendis PharmaAssetsYORVIPATHSKYTROFAYUVIWEL